MBRX Moleculin Biotech Inc gains 134% Jun 30, 2017

Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas. http://www.priceseries.com/trade/MBRX-Moleculin-Biotech-Inc-stock-gains-134-percent-a-Trade-Record-by-priceSeries-2017061620170630.html